Diagnostic, Therapeutic and Evolutionary Characteristics of Nasopharyngeal Cancer in Morocco

Elamin Marnouche1,*, Mohammed Elmarjany1, Rachid Razine2, Abdelhak Maghous1, Issam Lalya1, Khalid Andaloussi1, Amine Bazine1, Nohazagha1, Khalid Hadadi1, Hassan Sifat1 and Hamid Mansouri1

1Department of Radiotherapy, Mohamed V Military Hospital, Rabat, Morocco
2Department of Public Health, Laboratory of Biostatics, Clinical Research and Epidemiology, School of Medicine and Pharmacy of Rabat, Rabat, Morocco
3National Institute of Oncology, Rabat, Morocco

Abstract

Background: Nasopharyngeal carcinoma (NPC) is a radiosensitive and radio curable cancer, the radiation therapy (RT) is the mainstay of treatment with significant improvement in survival of patients. The aim of this study was to report the experience of Military Hospital Mohamed V in the management of NPC and their results.

Materials and methods: 83 no metastatic NPC patients managed at the radiotherapy department of Military Hospital Mohammed V of Rabat in Morocco, between January 2005 and December 2009, were included for investigation of their demographic, histological, therapeutic and follow-up characteristics. Statistical analysis of the data was carried out by the SPSS for Windows.

Results: The mean age was 44.5 ± 12.5 years with sex ratio 4:1. At diagnosis, rhinologic symptoms represented the most common clinical presentation, reported by 56 (67.5%) patients. Almost ninety percent (n=74) of patients presented UCNT histology. Most of the patients (85.5%) presented a locally advanced disease; stage III and IV. Therefore, forty patients (48.2%) were treated by concurrent chemoradiotherapy and 35 patients (42.2%) received induction chemotherapy. With a mean follow up of 70 ± 32 months, twenty nine patients (34.9%) died, 6 (7.2%) presented loco regional recurrence. While 11 (13.2%) patients presented distant recurrences. The five years overall survival (OS) was 68% ranging from 91% for both stage I and II, 79.3% for stage III to 40% for stage IV. The five years disease free survival (DFS) was 81.1%, whereas distant failure free survival (DFFS) was 84.1%. In multivariate analysis, the disease stage according to the seventh edition of the AJCC system was an independent prognostic factor.

Conclusion: Our outcomes in NPC are similar to the literature. Patients’ survival is directly impacted by the disease staging which is the most important prognostic factor. We hope to improve these results with the recent introduction of volumetric-modulated arc therapy machines.

Keywords: Nasopharyngeal carcinoma; Radiotherapy; Concomitant radio-chemotherapy

Abbreviations: NPC: Nasopharyngeal Carcinoma; OS: Overall Survival; DFS: Disease Free Survival; DFFD: Distant Failure Free Survival; AJCC: American Joint Committee on Cancer Staging System; TNM: Tumor Node Metastasis; RT: Radiation Therapy; IMRT: Intensity Modulated Radiotherapy; CT: Computed Tomography; MRI: Magnetic Resonance Imaging; SFU: 5 Fluoro Uracil; WHO: World Health Organization; IQR: Interquartile Range; EBV: Epstein Barr Virus; L-FFR: Local Failure-Free Rate; UCNT: Undifferentiated Carcinoma of Nasopharyngeal Type.

Background

Nasopharyngeal carcinoma (NPC) is a cancer arising from the nasopharynx epithelium. Within the boundaries of the nasopharynx, the tumor epicenter is frequently seen at the fossa of Rosenmüller, from where the tumor invades adjacent anatomical spaces or organs [1]. It differs from other head and neck squamous cell carcinomas in epidemiology, histology, natural history and response to treatment.

Nasopharyngeal carcinoma is an uncommon cancer in the most parts of the world and demonstrates a marked geographical variation. The age-adjusted incidence rate (per 100,000 people per year) among men ranges from 0.6 in the United States and Japan to 5.4 in Algeria, 5.8 in the Philippines, 11.0 in Singapore, 17.2 among Eskimos, Indians and Aleuts in Alaska to 17.8 and 26.9 in Hong Kong and Guangdong Province in Southern China, respectively [2-4]. In Morocco, there is a few data about incidence coming from several cities such as Casabalanca (3, 74 per 100,000 men/year versus 0, 88 per 100,000 women/year in 2004) [5] or rabat (3, 3 per 100,000 men per year versus 1, 8 per 100,000 women per year in 2005) [6]. The male-to-female incidence ratio is 2:1 to 3:1. [7]. A bimodal age distribution is observed in low-risk populations (such as Europe and North America). The first peak incidence arises between 15 to 25 years of age, with the second peak at 50 to 59 years of age [8-10]. In high-risk populations (including Southeast Asia, North Africa, Eskimos) [11,12], the peak incidence occurs in the fourth and fifth decades of life [8].

Since it is a clinically occult site, patients may remain asymptomatic for a prolonged period. The majority of patients has a locally and/or regionally advanced disease because of this asymptomatic period or, in some cases, due to a missed diagnosis [13,14]. Diagnosis of...
nasopharyngeal carcinoma is made by biopsy of the primary tumor or Fine-needle aspiration of a suspicious neck mass. The staging workup is performed, as disease staging according to the American Joint Committee on Cancer staging system AJCC is considered as the most important prognostic factor.

The development of radiation therapy (RT) revolutionized the management of nasopharyngeal carcinoma with the advent of megavoltage machines; the review by Moss [15] in 1965 showing 25% of patients alive at 5 years marked the first major breakthrough and established the role of RT as the primary modality of choice [16]. The adjunction of concurrent chemotherapy has more improved survival [17]. Recent development in RT techniques with Intensity-modulated radiotherapy (IMRT) further improved tumor coverage and organs at risk sparing.

The aim of this study was to report the experience of Military Hospital Mohamed V in the management of NPC.

Methods

This was a retrospective analytic study of 83 no metastatic NPC patients treated at the radiotherapy department of Military Hospital Mohammed V of Rabat in Morocco, between January 2005 and December 2009. Informed verbal consent was obtained from all patients to access and use their patient data. This study was submitted to and approved by research committee of military teaching hospital Mohamed V.

Patients were investigated by physical examination, fiberoptic examination, head and neck computed tomography CT, Magnetic resonance imaging MRI was not used currently, chest X-ray and abdominal ultrasound or thoracic and abdominal CT. Bone scan was performed if clinically indicated and for patients with locally advanced disease. The seventh edition of the AJCC system was used for disease staging.

All patients were treated by 3D radiotherapy technique using lateral opposing cervicofacial fields that encompassed the primary tumor and the upper neck nodes in one volume with a matching lower anterior cervical field for the lower cervical lymphatics in order to deliver a “prophylactic dose” 50 Gy, 2 Gy/fraction with a first lateral treatment fields reduction “spine off” at 40 Gy and electron therapy was used to complete dose in this area to respect spinal cord tolerance. Then, treatment fields were reduced again to reach 70 Gy in primary tumor and, if technically possible with photons X 6 MV, in pathologic cervical lymph nodes. If not, electron therapy was used to complete the dose in cervical lymphadenopathies. Regarding organs at risk, especially critical structures, we tried to respect tolerance’s threshold. However, radiation technique capabilities and disease stage (mostly locally advanced disease) were the main limitations. All patients were well informed of radiation risk in term of late toxicities.

The radiation treatment was used alone or with concurrent chemotherapy based on weekly cisplatin. Induction chemotherapy was administered for patients with locally advanced disease and different regimens were used based on cisplatin, anthracycline and 5FU.

The patient’s follow-up continued according to the following schedule: every 3 months for the first 2 years, every 6 months for the 3th, 4th and 5th years and then annually. Physical examination especially head and neck was performed in every visit. CT scan and fiberoptic examination were performed periodically to evaluate the response, to detect relapse and to assess late effects.

Data was collected using a well-structured checklist containing the important study parameters. The record collection included the patient related data (age at diagnosis and gender). Data included also clinical presenting symptoms (rhinologic, otologic, neurologic and lymph node syndromes), duration of symptoms (months) and other clinical data such as TNM classification and stage of disease according to the AJCC seventh edition 2010 and the histological type according to the world health organization WHO classification 1978. The type, the modalities of primary treatment (radiotherapy, chemotherapy, both), the date and the sites of relapse (local, loco regional, distant metastases), the follow up data, the death date and the date of last follow-up visit were also recorded.

Statistical analysis of the data was carried out by the SPSS 20 for Windows (SPSS, Inc., Chicago, IL, USA). Qualitative variables were presented as number and percentages. Quantitative variables were presented as mean±standard deviation for variables with normal distribution and as median and interquartile range (IQR) for variables with skewed distributions. Khi2 test was used to compare qualitative variables. The survival rate was analyzed with the Kaplan-Meier method.

Results

Eighty three patients were treated in our department. Table 1 summarizes their clinical, para clinical, histological characteristics and treatment modalities.

The mean age was 44.5 ± 12.5 years with sex ratio 4:1. At diagnosis, the rhinologic symptoms represented the most common clinical presentation (67, 5%). Otologic symptoms and adenomegaly were present respectively in 50 (60.2%), 44 (53%) patients. The median symptoms duration before histologic diagnosis was 8.9 months [7-12]. According to the former WHO classification, almost ninety percent of patients presented UCNT histology.

Most of patients (85.5%) presented a locally advanced disease (stage III and IV). Therefore, chemotherapy was usually administrated (concomitant or induction chemotherapy). Induction chemotherapy was delivered in 3.1 ± 0.52 cycles.

With a mean follow up of 70 ± 32 months, twenty nine patients (34.9%) died, 6 (7.2%) presented local or locoescalpel recurrence. While 11 (13.2%) patients presented distant recurrences, half of them occurred in bone. The mean duration of recurrence was 23.6 ± 17.28 months. Forty six (55.4%) patients were healthy and 8 (9.6%) patients were lost to follow up. We tried to contact all patients who were lost to follow-up by phone and by sending correspondence letter without response.

The five year overall survival (OS) was 68% ranging from 91% for both stage I and II, 79.3% for stage III to 40% for stage IV (Figures 1 and 2). The five year disease free survival (DFS) was 81.1% (Figure 1) whereas distant failure free survival (DFFS) was 84.1%.

In univariate analysis shown in Tables 2 and 3, the TNM stage impacted significantly OS (p=0.002), DFS (p= 0.001) and DFFS (p=0.002). T-category influenced significantly OS (p=0.012) and DFS (p=0.022) whereas N- category influenced significantly both DFS (p=0.019) and DFFS (p=0.001). Induction chemotherapy as treatment modality was a significant factor for both DFS (p=0.001) and DFFS (p=0.018). Moreover, duration between induction chemotherapy and radiotherapy also influenced statistically DFS (p=0.028) and DFFS (p=0.04). For OS, TNM stage was an independent prognostic factor in multivariate analysis (p=0.002). However, Multivariate analysis was not
performed for DFS and DFFS because of the relatively small number of events.

**Table 1:** Clinical, para-clinical, histological, therapeutic characteristics of patients.

<table>
<thead>
<tr>
<th>Item</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td>Age: 44.5 ± 12.5</td>
</tr>
<tr>
<td>Gender $</td>
<td>96 (83.1)</td>
</tr>
<tr>
<td>Clinical review $</td>
<td>14 (16.9)</td>
</tr>
<tr>
<td><strong>Lymph node syndromes $</strong></td>
<td>Unilateral: 36 (43.4)</td>
</tr>
<tr>
<td></td>
<td>Bilateral: 8 (9.6)</td>
</tr>
<tr>
<td><strong>Otologic syndrome $</strong></td>
<td>50 (60.2)</td>
</tr>
<tr>
<td><strong>Neurologic Syndrome $</strong></td>
<td>16 (19.3)</td>
</tr>
<tr>
<td><strong>Rhinoologic syndrome $</strong></td>
<td>56 (67.5)</td>
</tr>
<tr>
<td>Time between initial symptoms</td>
<td>8.9 [7-12]</td>
</tr>
<tr>
<td>and diagnosis* (months)</td>
<td></td>
</tr>
</tbody>
</table>

**Histology $**

- Type (I): 0
- Type (II): 9 (10.8)

**Para clinical review $**

- Cervicofacial CT: 83 (100)
- Nasopharyngeal MRI: 7 (8.4)
- Chest X ray: 78 (94)
- Abdominal ultrasound: 74 (89.2)
- Thoracic and abdominal CT: 11 (13.3)
- Bone scan: 55 (66.3)

**Stage $**

- I: 7 (8.4)
- II: 5 (6)
- III: 38 (45.8)
- IV: 33 (39.7)

**Treatment modalities $**

- Radiotherapy alone: 7 (8.4)
- Concurrent Chemoradiotherapy: 40 (48.2)
- Induction chemotherapy followed by Concurrent chemoradiotherapy: 35 (42.2)
- Induction chemotherapy regimen:
  - Cisplatin, anthracycline, 5FU: 7 (20)
  - Cisplatin, anthracycline: 23 (65.7)
  - Cisplatin, 5FU: 5 (14.3)
- Duration between induction chemotherapy and radiotherapy* (days): 43.24 ± 20.31

*Quantitative variable presented as mean ± standard deviation.

**Table 2:** Univariate analysis for factors influencing overall, disease free, distant failure free survival.

<table>
<thead>
<tr>
<th>Item</th>
<th>OS</th>
<th>DFS</th>
<th>DFFS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>p OR 95% IC</td>
<td>p OR 95% IC</td>
<td>p OR 95% IC</td>
</tr>
<tr>
<td>TNM stage</td>
<td>0.002 0.38 0.2-0.70</td>
<td>0.001 5.79 2.17-15.41</td>
<td>0.002 4.64 1.8-12</td>
</tr>
<tr>
<td>T category</td>
<td>0.012 0.56 0.36-0.86</td>
<td>0.022 2.10 1.11-3.98</td>
<td>0.34 - -</td>
</tr>
<tr>
<td>N category</td>
<td>0.24 - -</td>
<td>0.019 2.87 1.2-7</td>
<td>0.001 15 3.09-72</td>
</tr>
<tr>
<td>Parapharyngeal space involvement</td>
<td>0.054 - -</td>
<td>0.18 - -</td>
<td>0.26 - -</td>
</tr>
<tr>
<td>Gender $</td>
<td>0.98 - -</td>
<td>0.03 - -</td>
<td>0.76 - -</td>
</tr>
<tr>
<td>Histology $</td>
<td>0.55 - -</td>
<td>0.99 - -</td>
<td>0.99 - -</td>
</tr>
<tr>
<td>Induction chemotherapy</td>
<td>0.06 - -</td>
<td>0.001 13.9 2.8-69.4</td>
<td>0.018 5.6 1.34-23.4</td>
</tr>
<tr>
<td>Induction chemotherapy regimen</td>
<td>0.9 - -</td>
<td>0.69 - -</td>
<td>0.7 - -</td>
</tr>
<tr>
<td>Time between induction</td>
<td>0.054 - -</td>
<td>0.028 1.04 1.04-1.07</td>
<td>0.04 1.04 1.02-1.07</td>
</tr>
<tr>
<td>chemotherapy and radiotherapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time between initial symptoms</td>
<td>0.12 - -</td>
<td>0.81 - -</td>
<td>0.4 - -</td>
</tr>
</tbody>
</table>

$ Qualitative variable presented as number (n) and percentage (%).

*Quantitative variable presented as median and interquartile range.

**Figure 1:** Overall survival.

**Figure 2:** Overall survival reported by stage.
virus (EBV) DNA levels have a prognostic significance: higher levels influenced significantly both of DFS (p=0.019) and DFFS (p=0.001). In univariate analysis, T-category influenced TNM stage was an independent prognostic factor (p=0.002) impacting risk of distant metastasis and a worse survival. In multivariate analysis, general, advanced T-category is associated with worse local control and study, they reported DFFS of 81% versus 84.1% in our institution.

The TNM staging is the most important prognostic factor. In a study of 308 patients staged with MRI, Sze et al. [32,33] showed that those with GTV-P of <15 cm³ had significantly higher L-FFR than those with a value of ≥ 15 cm³ (97% vs. 82% at 3 years; p<0.01). Multivariate analysis confirmed GTV-P to be a strongly significant factor independent of T-category by the 1997 fifth edition of the AJCC, the risk of local failure increased by 1% for every 1-cm³ increase in volume.

Most series found significantly better prognosis for females and younger patients [34]; in this study, five women (17.2%) died versus 24 (82.8%) men. Forty percent of women who died were under 40 years of age versus 60% but it was not statistically significant.

Discussion

Chemoradiotherapy is the mainstay of NPC treatment. It improved significantly survival rates which decreased with disease stage. We found that the five years overall survival was 68%, ranging from 91% for stage I and II to 40% for stage IV. The TNM stage remained the most important prognostic factor.

The study included 2687 patients, a five years OS rate of 75% rates from series ranged from 36% to 58% [18-23]. Lee et al. found in a retrospective study including 2687 patients, a five years OS rate of 75% versus 60% but it was not statistically significant.

Late toxicities

<table>
<thead>
<tr>
<th>Toxicities</th>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trismus</td>
<td>39.4 (n=33)</td>
</tr>
<tr>
<td>Hyposialia (grade3)*</td>
<td>38.5 (n=32)</td>
</tr>
<tr>
<td>Cervical fibrosis</td>
<td>19.3 (n=16)</td>
</tr>
<tr>
<td>Otologic disorders</td>
<td>61.5 (n=48)</td>
</tr>
</tbody>
</table>

*According to CTCAE v3.0

Table 3: Proportion of late toxicities.

Five women (17.2%) died versus 24 (82.8%) men. Forty percent of women who died were under 40 years of age versus 60% but it was not statistically significant.

Depending on the degree of differentiation, nasopharyngeal carcinoma was categorized into three pathological subtypes, on the basis of WHO criteria, as follows: (I) squamous cell carcinoma, (II) no keratinizing carcinoma, and (III) undifferentiated carcinoma (UCNT; undifferentiated carcinoma of nasopharyngeal type) [35]. In the current World Health Organization (WHO) pathologic classification, [36] released in 2005, types II and III were combined into a single category of non-keratinizing carcinoma. A third category, the basosquamous carcinoma, was added. Of note, the former WHO classification remains quite commonly used. Although not all studies found histology to be an independent prognostic factor, [37,38] many found no keratinizing and undifferentiated carcinomas to be more radiosensitive and offer better prognosis than keratinizing squamous cell carcinoma [39-41]. We found that histology did not affect overall survival (p=0.55).

The role of induction chemotherapy followed by either RT alone or concurrent chemoradiotherapy is unclear. The MAC-NPC meta-analysis included data from 1039 patients included in six trials [17]. There was a statistically significant improvement in progression free survival (47 versus 39 percent at 5 years, HR 0.81, 95% CI 0.69-0.95). However, the difference in overall survival was not statistically significant (57 versus 55 percent at 5 years, HR 0.96, 95% CI 0.80-1.16). In a multicenter phase III trial conducted by Sun Yat-sen University at 10 centers in China, 480 patients with stage III-IVB, node-positive disease were randomly assigned to sequential chemotherapy with three cycles of docetaxel, cisplatin, and fluorouracil (TPF) followed by concurrent cisplatin plus RT, or to concurrent cisplatin plus RT
alone without adjuvant chemotherapy [42]. Failure-free survival at three years was significantly better in those receiving induction TPF compared with concurrent chemoradiotherapy alone (80 versus 72 percent, HR 0.68, 95% CI 0.48-0.97). The three-year overall survival rate was also significantly better in those receiving induction TPF (92 versus 86 percent, HR 0.59, 95% CI 0.36-0.95). Distant metastases were significantly reduced, and local regional failure was lower, although not significantly, in the induction arm [42]. We found that induction chemotherapy influenced DFS (p=0.001) and DFFS (0.018) in univariate analysis. Moreover, time between induction chemotherapy and radiotherapy also influenced statistically DFS (p=0.028) and DFFS (p=0.04). In theory, induction chemotherapy may control micrometastases earlier and facilitate RT planning by downstaging locally advanced tumors, especially for large T4 lesions, advanced nodal disease, or when delivery of a full course RT is challenging due to close proximity to critical structures [43]. Therefore, it seems reasonable that time between induction chemotherapy and RT could have an effect on survival. Induction chemotherapy was typically given 3 weeks prior to the initiation of RT [44].

Intensity-modulated radiotherapy (IMRT) has supplanted conventional radiotherapy in the treatment of NPC in an increasing number of institutions throughout the world. In centers where modern radiation technology is available, IMRT is the preferred method. Briefly, this technique caters for delivery of tumoricidal doses to gross tumor and subclinical disease, while minimizing doses to adjacent normal tissues. The recent improvement in disease control and survival in patients with nasopharyngeal carcinoma is partly attributable to IMRT [1]. A review of 1593 patients who were treated at a single institution with progressive radiotherapy techniques (2D radiotherapy, 3D radiotherapy, and IMRT) over two decades (1994 to 2010) also showed increased disease-specific and overall survival in individuals who received IMRT [45]. In a randomized study by Peng and colleagues, IMRT contributed to an absolute improvement in 5-years loco regional control of 7.7% compared with conventional 2D radiotherapy; [46]

The relatively small number of patients was the main limitation of this study. However, we did this choice to have a sufficient follow-up time. A lack of reporting toxicities (grading) was also noted. Therefore more rigor will be needed and procedures will be established to correct this lack of reporting.

Conclusion

Our results in NPC management are similar to the literature. Patient's survival is directly impacted by the disease staging which is the most important prognostic factor. We hope to improve these results with the recent acquisition of volumetric-modulated arc therapy machines.

Competing Interest

The authors declare that they have no competing interests.

Funding

Special thanks are due to the Faculty of Medicine and Pharmacy of Rabat; the source(s) of funding for all authors.

Authors’ Contribution

E.M. and M.E. performed research and share the first position on article; E.M., R.R and A.M., analyzed data statistically; E.M. and A.M., collected the clinical data; K.A., A.B., I.L., K.H., H.S., N.Z and H.M, designed and coordinated research and drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgement

All the authors are thankful for providing the necessary facilities for the preparation the manuscript.

References

26. e QT, Jones CD, Yau TK (2005) A comparison study of different PCR assays


